Animal Health Professionals Site

9 March 2015

New anti-inflammatory pour-on for cattle a world first

MILTON KEYNES, UK, March 9 2015 – It’s now easier for farmers to administer a proven non-steroidal anti-inflammatory drug (NSAID) to their cattle, thanks to the launch of an innovative new product that can be absorbed through the skin.

New FINADYNE Transdermal from MSD Animal Health (a division of Merck & Co., Inc., Kenilworth, NJ, USA.) has been granted a transdermal licence for treating bovine respiratory disease, making it the world’s first non-parasiticide cattle product to become available as a pour-on.

“Uniquely, FINADYNE Transdermal combines rapid efficacy with its novel, needle-free administration route. After applying to the skin it works fast – as quickly as two hours after treatment,” explains Dr. Martin Behr, technical manager at MSD Animal Health.

“The availability of this innovative new product means cattle producers will no longer have to struggle with the difficulty of injecting cattle showing signs of pneumonia. In addition, use of a pour-on NSAID means no needle-site lesions that can reduce the value of a carcass or compromise hide quality.”

Dr. Behr adds that the time taken by cattle producers to handle and treat animals should be much reduced by using a transdermal NSAID.  Farmers will also make savings on syringes and needles.

The new pour-on comes in pre-calibrated packaging and uses a bottle that’s designed for easy and accurate application along an animal’s back.

FINADYNE Transdermal has received a POM-V classification. Further information is available from veterinary practices.

Use medicines responsibly. For more information visit:

FINADYNE Transdermal is available from veterinary surgeons from whom advice should be sought. FINADYNE Transdermal contains flunixin. POM-V. FINADYNE Transdermal is the property of Intervet International B.V. or affiliated companies or licensors and is protected by copyrights, trademark and other intellectual property laws. Copyright © 2014 Intervet International B.V. All rights reserved.

Further information is available from: MSD Animal Health, Walton Manor, Walton, Milton Keynes MK7 7AJ. Tel: 01908 685685 

About MSD Animal Health

Today's MSD is a global healthcare leader working to help the world be well. MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, NJ, USA., is the global animal health business unit of MSD. Through its commitment to the Science of Healthier Animals™, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit or connect with us on LinkedIn.

MSD forward-Looking Statement

This presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of MSD’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; MSD’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of MSD’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

MSD undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in MSD’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (